Ongoing Acquisition of New Collaborative Drug Discovery Research Agreements
First written in FY2023. 5 of 10 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「With Switzerland-based SpiroChem AG, with which we agreed in December 2025 to conduct joint exploratory research on mRNA-targeted compounds, we held repeated discussions on the details of the joint research and entered into an agreement in May 2026.」
The company entered into a PREPARATORY RESEARCH AGREEMENT with SpiroChem AG dated 8 May 2026. The research period is 1 year from 8 May 2026. - FY2025AdvancedAnnual report
「As a result, the status of achievement of the KPIs, the principal indicators of our management targets for the fiscal year, was as follows: 3 new contracts were signed against an annual target of 4; the target for in-house pipeline creation was achieved with 1 patent application; and business revenue fell short of the target.」
In FY2025, the company signed new agreements with 3 companies. Although this was 1 short of the annual target of 4, concrete progress in acquiring agreements and partnerships included the agreement with Mitsubishi Gas Chemical Company, Inc. as of FY2025-H1 and the agreement on joint exploratory research with Switzerland-based SpiroChem AG. - 2026-03-02OtherGeneral Meetings of Shareholders
「To secure new contracts, we introduced our technology to pharmaceutical companies and other companies in Japan and overseas.」
The company continued activities to secure new contracts. It signed 3 contracts against an annual target of 4, so the target was not treated as achieved. - FY2025-H1AdvancedAnnual report
「During the interim accounting period, we newly entered into a joint research agreement with Mitsubishi Gas Chemical Company, Inc.」
There was concrete progress in acquiring new partners through the conclusion of an agreement with Mitsubishi Gas Chemical Company, Inc. in the first half of 2025. This is recorded as progress toward the target, not as achievement of the existing target of signing 2 agreements every year from 2025 onward. - FY2024-H1RestatedAnnual report
「To secure additional partners, we approached pharmaceutical companies in Japan and overseas that are interested in mRNA-targeted small-molecule drug discovery, including by introducing our platform technology.」
The company continues business-development activities, including technology introductions to pharmaceutical companies in Japan and overseas, to acquire new partners. - FY2024-Q1RestatedAnnual report
「To acquire new partners, in addition to negotiations with pharmaceutical companies under confidentiality agreements, we actively introduced our platform technology to pharmaceutical companies in Japan and overseas that are interested in our mRNA-targeted small-molecule drug discovery, seeking to increase the number of companies with which we can negotiate under confidentiality agreements. We will focus on business-development activities to acquire new partners in the current and following fiscal years.」
To acquire new partners, the company continues negotiations under existing confidentiality agreements while introducing its technology to pharmaceutical companies in Japan and overseas. - FY2023First statedAnnual report
「We are currently negotiating contracts with 4 pharmaceutical companies under CDAs. Based on these analyses, we have set the conclusion of agreements with 2 of these companies in 2024 as an indicator of achieving our target. From 2025 onward, we are conducting business-development activities to secure enough CDAs to support our target of signing agreements with 2 companies every year.」
The target is to sign agreements with 2 of the 4 companies under negotiation in 2024 and with 2 companies every year from 2025 onward.